<ѻýҕl>Transplant With Orca-T Reduced GVHD in Hematologic Malignanciesѻýҕl> Risk of relapse was also lower in the group who received the cell therapy Oct 03, 2022
<ѻýҕl>Response-Based Ponatinib Dose Reduction a Win-Win in Chronic-Phase CML?ѻýҕl> Strategy applied in OPTIC trial may mitigate adverse events without sacrificing benefit Sep 29, 2022
<ѻýҕl>Magrolimab-Azacitidine Shows Promise in Untreated High-Risk MDSѻýҕl> About a third of patients, including those with TP53 mutations, achieved complete remission Sep 29, 2022
<ѻýҕl>'Unparalleled Times' in Hematology, but Workforce Issues Persistѻýҕl> "This is the most exciting time ever" to be a hematologist, says ASH President Jane Winter, MD Sep 26, 2022 video
<ѻýҕl>What's on Tap at the Society of Hematologic Oncology's 10th Annual Meetingѻýҕl> Emphasis on novel biological approaches in treating patients with hematologic malignancies Sep 26, 2022
<ѻýҕl>CAR-T Therapy Effective in Youngest Kids With ALLѻýҕl> Analysis shows safety and outcomes equivalent to those reported in older children Sep 08, 2022
<ѻýҕl>Low-Dose Hypomethylating Agents in Lower-Risk MDS Yield Promising Outcomesѻýҕl> Overall response rates were 67% with decitabine, 48% with azacitidine Aug 22, 2022
<ѻýҕl>Two More Patients With HIV Surviving Without Antiretroviralsѻýҕl> Functional cures now seen in 5 patients Jul 29, 2022
<ѻýҕl>'Rogue' Online Pharmacies Are Dispensing Cancer Drugsѻýҕl> Shady sites with little oversight are selling imatinib for much less than U.S. retail price Jul 29, 2022
<ѻýҕl>Zanubrutinib Wins in First-Line CLL for Older Patientsѻýҕl> The BTK inhibitor proves superior to bendamustine-rituximab in phase III trial Jul 08, 2022
<ѻýҕl>FDA Warns of Increased Mortality Risk With Duvelisibѻýҕl> Drug approved for adults with CLL/SLL Jul 01, 2022
<ѻýҕl>FDA Panel Backs Gene Tx for Degenerative Brain Disorder in Kidsѻýҕl> Advisers unanimously recommend approval for pediatric ALD patients without HLA-matched donors Jun 10, 2022
<ѻýҕl>FDA Pulls Lymphoma Approvals for PI3K Inhibitor Umbralisibѻýҕl> Worse overall survival observed despite improvements in progression-free survival Jun 01, 2022
<ѻýҕl>Allo-Transplant With Omidubicel Hints at Longer-Term Benefits Tooѻýҕl> "Viable" option for patients eligible for umbilical cord blood transplantation, investigator says Apr 27, 2022
<ѻýҕl>Eprenetapopt-Based Combo Impresses in TP53-Mutant AML/MDSѻýҕl> 1-year relapse-free survival rate of 60% with maintenance therapy after transplant Apr 25, 2022
<ѻýҕl>9/11 Responders More Likely to Carry Genetic Mutations Tied to Cancerѻýҕl> Clonal hematopoiesis seen in 10% of firefighters, medical personnel on the scene after WTC attack Mar 07, 2022
<ѻýҕl>Third Person 'Cured' of HIV via Transplantѻýҕl> U.S. woman with leukemia gets cord blood resistant to HIV Feb 16, 2022
<ѻýҕl>Women More Likely to Experience Severe Toxicity of Cancer Treatmentsѻýҕl> Increased risk was particularly pronounced among those receiving immunotherapy Feb 14, 2022
<ѻýҕl>Illusionist Criss Angel's Son's Acute Leukemiaѻýҕl> Famed magician speaks about the long battle Feb 09, 2022
<ѻýҕl>Targeted Agent Improves Survival in FLT3-Positive Acute Myeloid Leukemiaѻýҕl> OS, EFS improved versus historical controls with addition of midostaurin to chemotherapy Dec 17, 2021
<ѻýҕl>Another Study Reinforces Chemo-Free Therapy for Newly Diagnosed CLLѻýҕl> Ibrutinib-rituximab extends PFS versus chemoimmunotherapy, especially in unmutated disease Dec 16, 2021
<ѻýҕl>Can Dasatinib Dose Be Halved in Low-Risk CML?ѻýҕl> Lower dose associated with improved tolerability, similar responses in propensity score analysis Dec 14, 2021
<ѻýҕl>Gentler Regimen Leads to High Response Rate in Older Patients With B-Cell ALLѻýҕl> One-year OS rate of 78% with fractionated inotuzumab ozogamicin exceeds 60% historical rate Dec 13, 2021
<ѻýҕl>Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Ratesѻýҕl> Combined with obinutuzumab, plus or minus ibrutinib, outperforms chemoimmunotherapy Dec 13, 2021
<ѻýҕl>Upfront IDH1 Inhibitor Triples Survival in Older AMLѻýҕl> Median OS for ivosidenib-azacitidine reached 2 years in patients ineligible for intensive therapy Dec 11, 2021
<ѻýҕl>Next-Gen MRD Testing Predicts Acute Leukemia Relapse After CAR-Tѻýҕl> Nearly all patients with detectable disease relapsed or progressed to transplant, other therapies Dec 01, 2021
<ѻýҕl>Novel Triplet Yields Undetectable MRD Status in 90% of CLL/SLL Patientsѻýҕl> Zanubrutinib plus obinutuzumab and venetoclax was also well tolerated Nov 29, 2021
<ѻýҕl>Pegylated Interferon Wins FDA Approval for Polycythemia Veraѻýҕl> Majority of patients attained complete hematologic response with ropeginterferon alfa-2b Nov 15, 2021
<ѻýҕl>A Gentler Standard for Acute Promyelocytic Leukemia in Kidsѻýҕl> ATRA/arsenic trioxide without maintenance therapy resulted in 99-100% survival at 2 years Nov 11, 2021
<ѻýҕl>FDA Approves STAMP Inhibitor for Chronic Myeloid Leukemiaѻýҕl> Patients treated with two or more TKIs and those with T315I mutation gain new option Nov 01, 2021
<ѻýҕl>What Happens When All the Great Doctors Are Gone?ѻýҕl> In commemoration of the late Elihu (Eli) Estey, MD Oct 13, 2021
<ѻýҕl>Life Expectancy Still Lower for Blood or Marrow Transplant Recipientsѻýҕl> Although late mortality has decreased over the past 40 years Sep 09, 2021
<ѻýҕl>Anti-CD7 CAR-T Therapy Yields High Response Rate in Acute Leukemiaѻýҕl> Complete responses in 18 of 20 patients with relapsed/refractory T-cell ALL Aug 04, 2021
<ѻýҕl>Add-On Venetoclax Promising in Younger, Fit AML Patientsѻýҕl> "Safe and feasible intensive regimen" in small single-center study Jul 30, 2021
<ѻýҕl>IVF Babies at No Increased Risk of Childhood Cancersѻýҕl> No associations seen with intracytoplasmic sperm injection or frozen embryo transfer, study found Jul 02, 2021
<ѻýҕl>Ethics Consult: Help Family Have 'Savior Child' for Marrow Donation? MD/JD Weighs Inѻýҕl> You voted, now see the results and an expert's discussion Jun 25, 2021
<ѻýҕl>Fixed-Duration, All-Oral Regimen Slows CLL Progressionѻýҕl> Near-80% reduction in PFS hazard with ibrutinib-venetoclax versus obinutuzumab-chlorambucil Jun 16, 2021
<ѻýҕl>Zanubrutinib Tops Ibrutinib in Relapsed or Refractory CLLѻýҕl> Better overall response rate, less cardiotoxicity, with second-generation BTK inhibitor Jun 14, 2021
<ѻýҕl>COVID Vaccine Protection; 'Until You Die From the Cancer'; What's Palliative Care?ѻýҕl> News, features, and commentary about cancer-related issues Jun 10, 2021
<ѻýҕl>Acalabrutinib Offers Less Wear and Tear on the Heart in CLL Patientsѻýҕl> BTK inhibitor had less cardiotoxicity than ibrutinib, but similar efficacy Jun 07, 2021